Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Vertex Pharma: Analysts Say Buy This 'Growth Champion'

2018-08-13 seekingalpha
Not all world heavyweight champions are found in the boxing ring. Consider global biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX). This drug maker is one to watch. Just this last June, the company landed #23 on Forbes’ Global 2000: Growth Champions List. The big rare disease player is making waves in the biotech universe.
VRTX GLPG

8
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2

2018-08-08 zacks
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) reported a loss of 6 cents per share in the second quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 8 cents but wider than the year-ago loss of 5 cents.
SGEN VRTX CPRX OAS GLPG

0
Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected

2018-08-07 zacks
Arena Pharmaceuticals, Inc. (ARNA - Free Report) reported a loss of 65 cents per share for the second quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 62 cents. The year-ago loss was 77 cents per share.
SGEN ARNA VRTX GLPG

0
Galapagos 2018 Q2 - Results - Earnings Call Slides

2018-08-06 seekingalpha
The following slide deck was published by Galapagos in conjunction with their 2018 Q2 earnings call.
GLPG

0
Galapagos' (GLPG) CEO Onno van de Stolpe on Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Ladies and gentlemen, good day, and welcome to the Galapagos results webcast. At this time, I would like to turn the conference over to Elizabeth Goodwin. Please go ahead ma'am.
GLPG MS

8
Can the Rally in Galapagos (GLPG) Shares Continue?

2018-07-31 zacks
Galapagos NV (GLPG - Free Report) has been on the move lately as the stock has risen by 23.4% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue?
CWH GLPG

1
Galapagos (GLPG): Moving Average Crossover Alert

2018-07-27 zacks
Galapagos NV (GLPG - Free Report) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for GLPG broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend.
FSWB GLPG NVR TRN FSBW

0
Galapagos and MorphoSys Ink Deal with Novartis for $1.111 Billion+

2018-07-20 biospace
Galapagos NV, headquartered in Mechelen, Belgium, and MorphoSys, based in Munich, Germany, signed an exclusive development and commercialization deal with Swiss-based Novartis. The agreement is built around MOR106, an IgG1 monoclonal antibody directed against IL-17C that was created in a collaboration between MorphoSys and Galapagos. MOR106 is being developed for the treatment of inflammatory diseases.
GLPG

0
Ad hoc: MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Novartis and MorphoSys Increases its Financial Guidance for 2018

2018-07-19 accesswire
PLANEGG/MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / July 19, 2018 / MorphoSys AG (NASDAQ: MOR), (FSE: MOR), (XETRA: MOR) announces today that MorphoSys and Galapagos NV have entered into a worldwide, exclusive agreement with Novartis Pharma AG covering the development and commercialization of their joint program MOR106. MorphoSys furthermore announces that, in consequence of this agreement with Galapagos and Novartis, it increases its financial guidance for the year 2018 pending clearance by the U.
MOR MPSYF MPSYY GLPG

0
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Pharma Partner

2018-07-19 accesswire
- Exclusive global license agreement with Novartis on MOR106 - MOR106, a monoclonal antibody directed against IL-17C, will be developed further in atopic dermatitis (AtD) and potentially other indications - Up-front payment of EUR 95 million (USD 111 million*) and potential milestone payments of up to approximately EUR 850 million (USD 1 billion*) plus royalties up to low-teens to low-twenties - Novartis to bear all future research, development, manufacturing and commercialization costs related to MOR106
MOR MPSYF MPSYY GLPG

1
Novartis to pay as much as $1 billion for skin drug rights

2018-07-19 livemint
Geneva: Novartis AG agreed to buy the rights to a skin-disease drug from developers Galapagos NV and MorphoSys AG in a deal that could reach $1 billion as Chief Executive Officer Vas Narasimhan centers the Swiss drugmaker on developing innovative prescription medicines.
REGN MPSYF MPSYY NVS GLPG

1
Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis

2018-07-19 globenewswire
Basel, July 19, 2018 - Novartis announced today that it has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) regarding their compound MOR106. Under the agreement, Novartis acquires the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Novartis will make an upfront payment of EUR 95 million to Galapagos and MorphoSys, and additional payments, royalties and fees pending achievement of agreed milestones.
MPSYF MPSYY NVS GLPG

1
MorphoSys en Galapagos tekenen wereldwijde licentieovereenkomst voor MOR106 met top farma partner

2018-07-19 globenewswire
Mechelen, België en Planegg / München, Duitsland; 19 juli 2018; 7.15 CET; gereglementeerde informatie - Galapagos NV (Euronext & NASDAQ: GLPG) en MorphoSys AG (FSE: MOR; Prime Standard-segment, TecDAX; NASDAQ: MOR) kondigen vandaag aan dat zij een wereldwijde, exclusieve overeenkomst zijn aangegaan met Novartis Pharma AG voor de ontwikkeling en commercialisering van hun gezamenlijke programma MOR106.
MOR MPSYF MPSYY GLPG GLPG

2
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

2018-07-19 globenewswire - 1
Mechelen, Belgium and Planegg/Munich, Germany; 19 July 2018; 7.15 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today that they have entered into a worldwide, exclusive agreement with Novartis Pharma AG covering the development and commercialization of their joint program MOR106.
MOR MPSYF MPSYY GLPG GLPG

59
Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha - 6
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it.
BLU CYTX TEVA ISR TEVVF ZYNE NGS AVXL SNGX VRX INSP ACRS CYTXW BLUSF CELG CTYX OCX GLPG KMPH VRX GLPG CTIC CTI EGRX XLRN TEVJF PTCT

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...